Drugs / T900607
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00054262 | Nov 2002 → Mar 2004 | liver cancer | University Hospitals Seidman Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00054249 | Sep 2002 → Oct 2004 | gastric cancer | University Hospitals Seidman Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00048529 | Sep 2002 → ? | gastric cancer, neoplasm of esophagus | Tularik | Suspended | No outcome recorded |
| Phase 2 | NCT00043459 | Jul 2002 → Mar 2003 | non-Hodgkin lymphoma | Tularik | Terminated | No outcome recorded |
| Phase 2 | NCT00043433 | Jul 2002 → ? | hepatocellular carcinoma | Tularik | Unknown | No outcome recorded |
| Phase 2 | NCT00043446 | Jul 2002 → ? | ovarian neoplasm | Tularik | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T900607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00043446 ↗ |
| Modality | Small molecule | — CHEMBL4297440 ↗ |
| Route | Intravenous | “intravenous T900607-sodium” NCT00043433 ↗ |